SCHEMBL201947

SCHEMBL201947

CCCc1ccc(-c2ccc(C(=O)NC(CF)C(=O)OC)cc2)cc1

nearest known ligand 0.69

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 7/20 0.69
TAS1R1 Q7RTX1 7/20 0.69
L3MBTL1 Q9Y468 2/20 0.51
PLK1 P53350 1/20 0.49
CTSS P25774 1/20 0.47
GAA P10253 3/20 0.46
RAB9A P51151 2/20 0.46
CYP26A1 O43174 1/20 0.46
NPC1 O15118 1/20 0.45
POLB P06746 2/20 0.45
CTDSP1 Q9GZU7 2/20 0.45
ALDH1A1 P00352 2/20 0.45
KDM4E B2RXH2 1/20 0.45
LMNA P02545 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
LNPEP Q9UIQ6 1/20 0.43
ACACB O00763 1/20 0.43
ACACA Q13085 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL203604 0.86 TAS1R3 (0.67) TAS1R3TAS1R1L3MBTL1PLK1CTSS
SCHEMBL203603 0.86 TAS1R3 (0.67) TAS1R3TAS1R1L3MBTL1PLK1CTSS
SCHEMBL201342 0.85 TAS1R3 (0.55) TAS1R3TAS1R1L3MBTL1PLK1CTSS
SCHEMBL201362 0.84 TAS1R3 (0.65) TAS1R3TAS1R1L3MBTL1PLK1CTSS
SCHEMBL201908 0.83 L3MBTL1 (0.76) TAS1R3TAS1R1L3MBTL1PLK1GAA
SCHEMBL201891 0.83 L3MBTL1 (0.76) TAS1R3TAS1R1L3MBTL1PLK1GAA
SCHEMBL200816 0.83 TAS1R3 (0.63) TAS1R3TAS1R1L3MBTL1PLK1CTSS
SCHEMBL4197725 0.82 TAS1R3 (1.00) TAS1R3TAS1R1L3MBTL1PLK1CTSS
SCHEMBL4197727 0.82 TAS1R3 (1.00) TAS1R3TAS1R1L3MBTL1PLK1CTSS
SCHEMBL202434 0.81 TAS1R3 (0.57) TAS1R3TAS1R1L3MBTL1PLK1CTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088804-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2012-01-03 US disclosed
EP-2338878-A2 N-hydroxyamide derivatives possessing antibacterial activity Vicuron Pharmaceuticals, Inc. (US) 2011-06-29 EP disclosed
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. 2010-01-28 US disclosed
EP-1963262-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2008-09-03 EP disclosed
WO-2007069020-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY NAAA, HDHD5, HACL2 TAS1R3 1250/4885TAS1R1 1011/4885L3MBTL1 2179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.